These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16236972)

  • 1. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?
    Currie GP; Lee DK; Srivastava P
    Chest; 2005 Oct; 128(4):2954-62. PubMed ID: 16236972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of leukotriene receptor antagonists (LTRAs) as complementary therapy in asthma.
    Bjermer L; Diamant Z
    Monaldi Arch Chest Dis; 2002 Feb; 57(1):76-83. PubMed ID: 12174707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of moderate persistent asthma: inhalation corticosteroids in combination with long acting beta 2-adrenergic agonists (bronchodilators) then with leukotriene receptor antagonists (anti-inflammatory agents); the 'step-3-dilemma'].
    Diamant Z; Dekhuijzen PN
    Ned Tijdschr Geneeskd; 2003 Aug; 147(35):1681-5. PubMed ID: 14513539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists.
    Creticos PS
    Drugs; 2003; 63 Suppl 2():1-20. PubMed ID: 14984077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
    Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
    Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of bronchial asthma.
    Nelson HS
    Allergy Asthma Proc; 2001; 22(4):217-20. PubMed ID: 11552671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-2 agonist discussions in asthma and a review of current data.
    Erdinç M
    Tuberk Toraks; 2011; 59(2):205-12. PubMed ID: 21740399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukotriene Receptor Antagonists and Antiallergy Drugs.
    Tamada T; Ichinose M
    Handb Exp Pharmacol; 2017; 237():153-169. PubMed ID: 27826703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk assessment of long-acting beta2-agonists in asthma.
    Jackson CM; Lipworth B
    Drug Saf; 2004; 27(4):243-70. PubMed ID: 15003036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
    Naedele-Risha R; Dorinsky P; Craig TJ
    J Am Osteopath Assoc; 2001 Sep; 101(9):526-33. PubMed ID: 11575039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids: the step 3 dilemma.
    Lipworth BJ; Jackson CM
    Drugs; 2002; 62(16):2315-32. PubMed ID: 12396225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma.
    Patel YA; Patel P; Bavadia H; Dave J; Tripathi CB
    J Postgrad Med; 2010; 56(4):270-4. PubMed ID: 20935397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing symptoms and exacerbations in pediatric asthma.
    Verberne AA
    Pediatr Pulmonol Suppl; 1997 Sep; 15():46-50. PubMed ID: 9316102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment].
    Fal AM; Kopeć A
    Pneumonol Alergol Pol; 2010; 78(1):68-73. PubMed ID: 20162521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of the evidence.
    Vignola AM
    Drugs; 2003; 63 Suppl 2():35-51. PubMed ID: 14984079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of long-acting β agonists for the treatment of asthma: clearing the air.
    Rodrigo GJ; Castro-Rodríguez JA
    Thorax; 2012 Apr; 67(4):342-9. PubMed ID: 21515554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based asthma management.
    Kallstrom TJ
    Respir Care; 2004 Jul; 49(7):783-92. PubMed ID: 15222910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability profiles of leukotriene receptor antagonists and long-acting beta2-adrenoceptor agonists in combination with inhaled corticosteroids for treatment of asthma: a review.
    Colucci R; Fornai M; Tuccori M; Antonioli L; Pasqualetti G; Blandizzi C; Del Tacca M
    J Asthma; 2007; 44(6):411-22. PubMed ID: 17654125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of asthma medications in children.
    Tamesis GP; Covar RA
    Curr Opin Allergy Clin Immunol; 2008 Apr; 8(2):163-7. PubMed ID: 18317027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.